Technical Analysis for GLTO - Galecto, Inc.

Grade Last Price % Change Price Change
F 10.0 8.11% 0.75
GLTO closed down 3.55 percent on Friday, March 5, 2021, on approximately normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Down
Historical GLTO trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 8.22%
Calm After Storm Range Contraction 8.22%
Lower Bollinger Band Walk Weakness 8.22%
New 52 Week Low Weakness 8.22%
Outside Day Range Expansion 8.22%
Wide Bands Range Expansion 8.22%
Below Lower BB Weakness 8.22%
Down 3 Days in a Row Weakness 8.22%
Down 4 Days in a Row Weakness 8.22%
Lower Bollinger Band Touch Weakness 8.22%
Older End-of-Day Signals for GLTO ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Gapped Up (Full) 34 minutes ago
Rose Above Previous Day's High 34 minutes ago
Rose Above Lower Bollinger Band 34 minutes ago
Up 5% 34 minutes ago
Up 3% 34 minutes ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Galecto, Inc. Description

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of fibrosis related to non-alcoholic steatohepatitis, as well as development of other related indications, including cancer. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Clinical Medicine Biology Alcohol Inflammation Steatohepatitis Non Alcoholic Fatty Liver Disease Idiopathic Pulmonary Fibrosis Progressive Pulmonary Fibrosis Fibrosis Related Disease Related Diseases Breakthrough Therapy Copenhagen Fibrotic Disease Lectins mTOR Galectin Lung Diseases Myelofibrosis Treatment Of Fibrosis Galectin 3 Galecto Biotech

Is GLTO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 17.99
52 Week Low 9.02
Average Volume 18,985
200-Day Moving Average 0.00
50-Day Moving Average 12.34
20-Day Moving Average 11.56
10-Day Moving Average 10.84
Average True Range 0.76
ADX 24.45
+DI 8.44
-DI 30.52
Chandelier Exit (Long, 3 ATRs ) 10.87
Chandelier Exit (Short, 3 ATRs ) 11.29
Upper Bollinger Band 13.62
Lower Bollinger Band 9.51
Percent B (%b) -0.06
BandWidth 35.53
MACD Line -0.76
MACD Signal Line -0.52
MACD Histogram -0.2462
Fundamentals Value
Market Cap 227.41 Million
Num Shares 24.6 Million
Price-to-Sales 0.00
Price-to-Book 11.08
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.65
Resistance 3 (R3) 10.72 10.34 10.41
Resistance 2 (R2) 10.34 9.98 10.30 10.33
Resistance 1 (R1) 9.79 9.76 9.60 9.72 10.26
Pivot Point 9.41 9.41 9.31 9.37 9.41
Support 1 (S1) 8.86 9.05 8.67 8.79 8.24
Support 2 (S2) 8.48 8.83 8.44 8.17
Support 3 (S3) 7.93 8.48 8.09
Support 4 (S4) 7.86